|
|
Post by hellodolly on Apr 1, 2019 5:10:47 GMT -5
WESTLAKE VILLAGE, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. Pursuant to the agreement, MannKind is eligible to earn additional payments up to $37.5 million upon the achievement of other defined development milestones. MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.
MannKind also announced that it filed a new shelf registration statement on Form S-3 with the Securities and Exchange Commission on March 29, 2019, which, when effective, will replace the existing shelf registration statement that expires on April 27, 2019.
|
|
|
|
Post by winner on Apr 1, 2019 5:15:11 GMT -5
GOOD MORNING hellodolly
What a beautiful post to read to start my day.
Thanks so much...….. (Enjoy reading all of your post)
|
|
|
|
Post by liane on Apr 1, 2019 5:20:55 GMT -5
$2.08 premarket
|
|
|
|
Post by hellodolly on Apr 1, 2019 5:21:31 GMT -5
GOOD MORNING hellodolly What a beautiful post to read to start my day. Thanks so much...….. (Enjoy reading all of your post) Nice news out of the gate this morning of a milestone payment and some more clarity on the S3. "...when effective, will replace the existing shelf registration statement that expires on April 27, 2019."
The S3 is a non-issue.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 1, 2019 5:32:19 GMT -5
GOOD MORNING hellodolly What a beautiful post to read to start my day. Thanks so much...….. (Enjoy reading all of your post) Nice news out of the gate this morning of a milestone payment and some more clarity on the S3. "...when effective, will replace the existing shelf registration statement that expires on April 27, 2019."
The S3 is a non-issue.
Yes. But most longs here are jumpy as shit. With good reason, weve been through the ringer and back. Why couldnt have this been released along with the S-3 announcement? Save many of us from becoming alcoholics, even if only for a weekend. Mike if you are reading this. PR PR PR. We are the little guys, we need some additional info for things like this. PR PR PR. Throw us a little info, it would be very much appreciated. |
|
|
|
Post by ilovekauai on Apr 1, 2019 6:40:00 GMT -5
|
|
|
|
Post by ilovekauai on Apr 1, 2019 6:40:22 GMT -5
Nice news, except it's a $12.5 payment, not $125M payment. The link won't let me fix it!
|
|
|
|
Post by veritasfiliatemporis on Apr 1, 2019 7:09:50 GMT -5
I would like to stress the fact it was clear the new shelf registration statement was intended to replace the old one... A lot of bashing...
|
|
|
|
Post by matt on Apr 1, 2019 7:33:04 GMT -5
I would like to stress the fact it was clear the new shelf registration statement was intended to replace the old one... A lot of bashing... A shelf registration lets the company register its securities to be traded, it does not authorize the company to issue more shares. The SEC can only regulate the trading of securities because corporations are creatures of state law and it is the fifty states that regulate when and how securities are authorized and issued. There is no reason to fear significant dilution until, and unless, the company calls a special meeting to authorize an increase in shares. The fact that MNKD is legally formed in Delaware protects shareholders in this way, unlike incorporation in some states (e.g. Nevada) where shareholders do not get to vote on share increases. |
|
|
|
Post by akemp3000 on Apr 1, 2019 7:49:19 GMT -5
Matt...Thanks much for providing clear SEC explanations to a lot of issues that have been brought up on this board.
|
|
|
|
Post by bigchungus91354 on Apr 1, 2019 7:51:24 GMT -5
Got the milestone, very good news! India needs a trial, but we weren't counting on any revenue from there anyhow. This should (slowly) rise up toward 2.60. If they can get Afrezza sales on track we could see $3 soon. Cautiously optimistic!
|
|
|
|
Post by mannmade on Apr 1, 2019 8:24:54 GMT -5
Wonder if this will help the $2.38’s for April 9th?
|
|
|
|
Post by barnstormer on Apr 1, 2019 8:31:47 GMT -5
Wonder if this will help the $2.38’s for April 9th? What would have really helped would have been Cipla's success in getting Afrezza approved in India rather than the rejection they got today. Another fumble that probably could have been avoided if MNKD mangement would have driven the approval process rather than rely on a partner with no real skin in the game. When will they quit relying on others to do the heavy lifting when they have the studies and the talent (Kendall) to drive the process? Will Brazil end up the same way? |
|
|
|
Post by bigchungus91354 on Apr 1, 2019 8:37:58 GMT -5
Wonder if this will help the $2.38’s for April 9th? Still possible, but I'd say that's a pretty big long shot. |
|
|
|
Post by traderdennis on Apr 1, 2019 8:47:00 GMT -5
Wonder if this will help the $2.38’s for April 9th? Still possible, but I'd say that's a pretty big long shot. Touching 1.90 right now. Not looking good |
|
